Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.

NCT00720538 is registered in ClinicalTrials.gov with IRCCS Burlo Garofolo as lead sponsor.

NCT NCT00720538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00720538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.
Lead sponsor
IRCCS Burlo Garofolo
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2008
Completion date
June 30, 2012
Enrollment
84 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, inflammatory bowel diseases, ulcerative colitis